Telix Pharmaceuticals Limited (TLX:ASX)
$4.03
0.07 (1.77%)
MCAP $1.130B
Last trade 16.10pm 02/03/2021
20mins delayed
Latest Announcements
02/03/2021TLXTelix Pharmaceuticals Limited
02/03/2021TLXTelix Pharmaceuticals Limited
26/02/2021TLXTelix Pharmaceuticals Limited
147
MCap
26/02/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
26/02/2021TLXTelix Pharmaceuticals Limited
26/02/2021TLXTelix Pharmaceuticals Limited
26/02/2021 Price SensitivePSTLXTelix Pharmaceuticals Limited
22/02/2021TLXTelix Pharmaceuticals Limited
Company Overview
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
